Loading news...
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust.
Revolution Medicines stock tanks after a WSJ report said Merck has withdrawn from buyout talks over price.
An apparent suitor has withdrawn from talks about acquiring the biotech, according to a media report. That's particularly discouraging, given that this business was apparently discussing a deal in the tens of billions of dollars for Revolution.
Revolution Medicines (RVMD) reversed a lot of its recent rally on Monday after the Wall Street Journal reported that Merck (MRK) is no longer looking to buy the biotech firm. However, as George Tsilis explains, there may be more pressure pinning the stock beyond its potential missed acquisition story.
Merck & Co., Inc. (NYSE: MRK) has reportedly ended discussions to acquire cancer drug developer Revolution Medicines, Inc. (NASDAQ: RVMD) after the two sides disagreed on valuation.
Merck is no longer in discussions to buy cancer drug developer Revolution Medicines , the Wall Street Journal reported on Sunday.
The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion.
SG Americas Securities LLC increased its position in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 150.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,714 shares of the company's stock after buying an additional 6,436 shares during the period. SG Americas
Stock News DOJ subpoenas Fed chair spark backlash: Federal prosecutors served grand jury subpoenas to Jerome Powell over testimony on Fed HQ renovations, prompt
Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Shares of Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) have been given an average rating of "Buy" by the eighteen research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and four have assigned a strong buy
Defense, AI power demand and deal-driven catalysts powered last week's top large-cap winners, led by sharp surges in RGC, RVMD and a cluster of defense and data-center energy plays.
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total value of $980,000.00. Following the sale, the chief financial officer owned 108,065 shares in the company, valued
It's apparently in talks to be sold to a pharmaceutical industry titan. The price being discussed reaches into the tens of billions of dollars.
Dealmaking persists as creditors, buyers, and investors wrestle with debt, delays, and mega-merger ambitions.
Revolution is developing drugs that target a molecular driver of cancers.
Revolution Medicines (RVMD) remains a "Strong Buy", driven by advanced RAS [ON] inhibitor programs and robust clinical progress, notably with Daraxonrasib. Company's phase 3 RASolute-302 trial in metastatic PDAC RAS-mutant patients is a major catalyst, with data expected in 2026 and significant expansion potential. Buyout interest from major pharma, including rumored $28–32B bids, underscores RVMD's strategic value and enhances upside optionality.
Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.
Merck (MRK) is reportedly in talks to acquire Revolution Medicines (RVMD) for $28-$32 billion or more. This acquisition aims to strengthen MRK's oncology pipeli
TSM enjoys revenue surge, Nvidia adds CMO for brand recognition, jobs report due, and more